The price of GLP-1 drugs has attracted the scrutiny of lawmakers, and Novo Nordisk's chief executive Lars Fruergaard Jrgensen has agreed to appear at a Senate hearing next week to defend the pricing of the group's semaglutide-based therapies
It showed good differentiation vs insulin, DPP-4 (oral products from Merck&Co) or the first-generation GLP-1
Detox and long inpatient stays pull these averages up, so most people who use insurance or shorter programs pay considerably less
Therefore, serum potassium levels and platelet count should be monitored carefully during therapy [see Dosage and Administration (2.3)]
However, in the absence of data on peoples underlying medical risk factors, it is not possible to understand the extent to which this reflects true medical need, e.g
The recurring fee is the price of continuity, not a single drug purchase